title: Fatty acid use in glaucomatous optic neuropathy treatment.
abstract: The authors have studied the efficacy of an association of DHA, vitamin E and vitamin B complex (TROFINERV) in glaucomatous patients. The parameters evaluated were computerized visual field (CVF) and retinal contrast sensitivity (RCS). Thirty chronic simple glaucoma patients in good tensional compensation with local therapy were given TROFINERV oral therapy. The results show significant differences after 90 days of treatment both in the perimetric indices (MD, SF, CPSD; p < 0.05) and in the RCS frequency values (p < 0.05). In the light of the results obtained, the authors consider the use of such association to be a useful support in glaucomatous patient therapy for preventing or delaying the progress of damage.
authors.affiliation: Oculistics Clinic, University of Bologna.
authors.forename: M
authors.initials: M
authors.lastname: Cellini
authors.forename: N
authors.initials: N
authors.lastname: Caramazza
authors.forename: P
authors.initials: P
authors.lastname: Mangiafico
authors.forename: G L
authors.initials: GL
authors.lastname: Possati
authors.forename: R
authors.initials: R
authors.lastname: Caramazza
mesh_terms: D000284:Administration, Oral; D000368:Aged; D002908:Chronic Disease; D015350:Contrast Sensitivity / Q000187:drug effects; D004281:Docosahexaenoic Acids / Q000008:administration & dosage / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005231:Fatty Acids, Unsaturated / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005902:Glaucoma, Open-Angle / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009901:Optic Nerve Diseases / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome; D014794:Visual Fields / Q000187:drug effects; D014803:Vitamin B Complex / Q000008:administration & dosage / Q000627:therapeutic use; D014810:Vitamin E / Q000008:administration & dosage / Q000627:therapeutic use